MET inhibitor resistance in patients with MET exon 14-altered lung cancers.

9006 Background: MET exon 14 alterations comprise a novel class of lung cancer drivers. MET tyrosine kinase inhibitors (TKIs) are active in patients with these cancers, but objective response rates (ORRs) are modest (~30%-40%). A subset of these cancers may harbor intrinsic resistance. Moreover, patients with initial benefit invariably develop acquired resistance. We set out to identify potential resistance mechanisms. Methods: We studied patients with stage IV MET exon 14-altered lung cancers who received a MET TKI. When feasible, tumor and/or plasma samples were collected, prioritizing paired pre- and post-TKI collection. Tumor samples underwent targeted mass spectrometry analysis (Nantomics) and DNA- (including MSK-IMPACT)/RNA-based (MSK-Fusion) next-generation sequencing (NGS). Plasma cfDNA underwent targeted NGS. ORR and progression-free survival (PFS) were assessed (RECIST v1.1). Results: 74 patients received a MET TKI (1 TKI n = 55; ≥2 TKIs n = 19). 91% received crizotinib as their 1st TKI. Pre-TKI MET levels in tumor tissue (range 0-2120 amol/µg) were associated with outcomes: ORR 63% (n = 7/11) and median PFS 6.9 mos with detectable MET vs ORR 0% (n = 0/5) and median PFS 4.6 mos with undetectable MET (HR for PFS 0.3). Pre-TKI RAS pathway activation was associated with response: ORR 0% (n = 0/6) with KRAS/NF1/RASA1 mutation vs ORR 29% (n = 25/87) in others. Similar outcomes were observed with pre-TKI KRAS expression (n = 16, all with detectable KRAS levels): ORR 0% (n = 0/2) in KRAS ≥700 amol/µg vs ORR 50% (n = 7/14) < 700 amol/µg. Acquired resistance (Jackman criteria) was seen in 29 patients, 9 with paired pre-/post-treatment samples. On-target acquired resistance was found in 2/9 patients (22%): MET D1228N (n = 1), HGF amplification (n = 1). Potential off-target acquired resistance mechanisms were found in 5/9 pts (44%): KRAS G13V (n = 1), RASA1 S742* (n = 1), MDM2 amplification (n = 2), EGFR amplification (n = 1). Conclusions: Lack of MET expression or RAS pathway activation is associated with poor MET TKI outcomes in MET exon14-altered lung cancers. On-target acquired resistance is found in < 25% of patients; HGF amplification is a novel mechanism. Off-target intrinsic/acquired resistance may be mediated by RAS/MDM2/EGFR pathway activation.

• Publication year

  2019

• Venue

  Journal of Clinical Oncology

• Publication date

  2019-05-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2019.37.15_SUPPL.9006
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Recording and classifying MET receptor mutations in cancers

  2024cites this paper
• MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing

  2023cites this paper
• SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer

  2023cites this paper
• Crizotinib in Patients With MET-Amplified NSCLC.

  2021cites this paper
• Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report

  2021cites this paper
• A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations

  2021influential citation
• MET Exon 14 Skipping Alterations in Non-small Cell Lung Carcinoma—Current Understanding and Therapeutic Advances

  2021cites this paper
• Kinase drug discovery 20 years after imatinib: progress and future directions

  2021cites this paper
• When the MET receptor kicks in to resist targeted therapies

  2021cites this paper
• Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report

  2021cites this paper
• A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade

  2021cites this paper
• Targeting un-MET needs in advanced non-small cell lung cancer.

  2021cites this paper
• Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer

  2020cites this paper
• Skipping Expected Mechanisms of MET-Mediated Oncogenesis.

  2020cites this paper
• Non-small cell lung cancer targetable mutations: present and future

  2020influential citation
• Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations

  2020cites this paper
• MET-dependent solid tumours — molecular diagnosis and targeted therapy

  2020cites this paper
• Targeting MET Dysregulation in Cancer.

  2020cites this paper
• MET receptor in oncology: From biomarker to therapeutic target.

  2020cites this paper
• Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

  2020cites this paper
• The METeoric rise of MET in lung cancer

  2020cites this paper
• 二代测序技术在NSCLC中的临床应用中国专家共识(2020版)

  2020cites this paper
• SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

  2020cites this paper
• Narrative review: mesenchymal-epithelial transition inhibitors—meeting their target

  2020cites this paper
• Capmatinib for the treatment of non-small cell lung cancer

  2019cites this paper
• Highlights of ASCO

  2019cites this paper
• Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration

  2019cites this paper
• Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

  2019cites this paper
• Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

  2019cites this paper